SecBot SecBot
8-K ·Filed Apr 2, 2026

PALI

PALISADE BIO, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed7mo ago SEC0001493152-26-014822
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor enrollment progress in the Phase 2 UC trial as a key catalyst; assess whether the Iterative Health partnership meaningfully accelerates timelines. The $3M raise provides limited runway, so future financing needs should be watched.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.89
T+0 close · Apr 2, 2026 · via day close
Latest settled
+10.58%
T+60 · $2.09
Vs SPY
−3.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $1.89entry
  2. T+1 · 8mo ago +2.12%α +1.64% · $1.93
  3. T+5 · 7mo ago −3.70%α −7.32% · $1.82
  4. T+20 · 7mo ago +5.82%α −4.06% · $2.00
  5. T+60 · 5mo ago +10.58%α −3.58% · $2.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palisade Bio issued 1.54 million shares to an affiliate of Iterative Health for $3.0 million to support a clinical trial partnership for its ulcerative colitis drug PALI-2108. The company also entered into a master services agreement with Iterative Health to accelerate patient enrollment in the upcoming Phase 2 study.

Key Facts

  • Palisade Bio issued 1,536,885 shares of common stock to an affiliate of Iterative Health for $3.0 million ($1.952 per share)
  • Proceeds support collaboration with Iterative Health to expedite patient enrollment in the Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis
  • The share issuance was conducted under a private placement exempt from registration under Section 4(a)(2) of the Securities Act
  • The transaction represents approximately 4.9% of Palisade Bio's current market cap of $312M

Financial Impact

$3.0 million in gross proceeds from issuance of 1.54 million shares at $1.952 per share, representing 4.9% dilution based on current market cap

cashshare countdilution

Risk Factors

  • Dilution from share issuance may pressure stock price
  • Clinical trial delays or poor enrollment despite partnership
  • Limited funding size suggests need for additional capital in near term

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-014822
Document: 0001493152-26-014822-index-headers.html0001493152-26-014822
Document: 0001493152-26-014822-index.html0001493152-26-014822
Document: 0001493152-26-014822.txt0001493152-26-014822

Track record

14 reports on PALI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
  3. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
  4. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
  5. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
  6. Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
  7. Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
  8. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
  9. Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
  10. Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026